Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Urosure is a branded generic combination medication developed and marketed by Avogadro, primarily used for the prevention of kidney stones (urolithiasis) and the management of renal tubular acidosis. The formulation typically contains potassium citrate, magnesium citrate, and pyridoxine hydrochloride (Vitamin B6). Potassium and magnesium citrates act as urinary alkalizers, increasing the pH and citrate levels in the urine, which helps to inhibit the crystallization of stone-forming salts such as calcium oxalate and uric acid. Pyridoxine is included to act as a cofactor for the enzyme alanine-glyoxylate aminotransferase, thereby reducing the endogenous production of oxalate. Urosure is commonly administered as an oral solution (syrup) to maintain optimal urinary chemistry and prevent recurrent stone formation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on potassium citrate + magnesium citrate + pyridoxine.